Compounds > gefitinib
Page last updated: 2024-09-03

gefitinib and nvp-tae684

gefitinib has been researched along with nvp-tae684 in 4 studies

Compound Research Comparison

Studies
(gefitinib)		Trials
(gefitinib)		Recent Studies (post-2010)
(gefitinib)		Studies
(nvp-tae684)		Trials
(nvp-tae684)		Recent Studies (post-2010) (nvp-tae684)
5,2315662,91974063

Protein Interaction Comparison

ProteinTaxonomygefitinib (IC50)nvp-tae684 (IC50)
Tyrosine-protein kinase JAK2Homo sapiens (human)1.505
Serine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)0.065
Tyrosine-protein kinase ABL1Homo sapiens (human)1.048
Insulin receptorHomo sapiens (human)2.5164
Tyrosine-protein kinase Fes/FpsHomo sapiens (human)0.569
Macrophage colony-stimulating factor 1 receptorHomo sapiens (human)0.0501
Tyrosine-protein kinase LynHomo sapiens (human)1.308
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)1.385
Insulin-like growth factor 1 receptorHomo sapiens (human)0.0003
Hepatocyte growth factor receptorHomo sapiens (human)1.667
Proto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)0.002
Platelet-derived growth factor receptor betaHomo sapiens (human)3.22
Fibroblast growth factor receptor 1Homo sapiens (human)0.6175
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)1.146
Insulin receptor Rattus norvegicus (Norway rat)1.2
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.872
Fibroblast growth factor receptor 4Homo sapiens (human)0.652
Fibroblast growth factor receptor 3Homo sapiens (human)0.085
Non-receptor tyrosine-protein kinase TYK2Homo sapiens (human)2.309
Vascular endothelial growth factor receptor 2Homo sapiens (human)2.123
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.7385
Tyrosine-protein kinase ZAP-70Homo sapiens (human)1.598
Cytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)1.578
Ephrin type-B receptor 4Homo sapiens (human)1.3
ALK tyrosine kinase receptorMus musculus (house mouse)0.01
Angiopoietin-1 receptorHomo sapiens (human)0.5895
Macrophage-stimulating protein receptorHomo sapiens (human)1.634
Lysine--tRNA ligaseHomo sapiens (human)0.88
BDNF/NT-3 growth factors receptorHomo sapiens (human)2.018
Leucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)0.0323
Echinoderm microtubule-associated protein-like 4Homo sapiens (human)0.03
ALK tyrosine kinase receptorHomo sapiens (human)0.0138

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB1
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Bae, MK; Cho, BC; Haack, H; Hwang, SK; Jewell, SS; Kang, DR; Kim, HJ; Kim, HR; Kim, JH; Lim, SM; Ou, SH; Park, JK; Shim, HS; Shin, E; Soo, RA; Wang, J1

Other Studies

4 other study(ies) available for gefitinib and nvp-tae684

ArticleYear
Navigating the kinome.
    Nature chemical biology, 2011, Volume: 7, Issue:4

    Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology

2011
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Anaplastic Lymphoma Kinase; Antigens, Differentiation, B-Lymphocyte; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Crizotinib; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Frequency; Gene Rearrangement; Glutamates; Guanine; Histocompatibility Antigens Class II; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridines; Pyrimidines; Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; Smoking; Treatment Outcome

2013